Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 3 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Squamous Cell Carcinoma of Head and Neck 4Mouth Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma 3Oropharyngeal Neoplasms 2Rectal Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoid Interstitial Pneumonia 1Locally Recurrent Skin Squamous Cell Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Specimen Handling 6Magnetic Resonance Spectroscopy 5pembrolizumab 4Platinum 3Cisplatin 3Cetuximab 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3(225)Ac-DOTA-c(RGDyK) 3ipatasertib 2Radiotherapy, Intensity-Modulated 2Immunoglobulin G 2Disulfides 2merphos 1durvalumab 1cabozantinib 1atezolizumab 1X-Rays 1Surveys and Questionnaires 1Radiotherapy 1Radiosurgery 1Radiation 1Nivolumab 1Methotrexate 1Interviews as Topic 1Erlotinib Hydrochloride 1Docetaxel 1Celecoxib 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Hypopharyngeal Neoplasms × (225)Ac-DOTA-c(RGDyK) × 30 days × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06589804 2026-06-03

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

National Cancer Institute (NCI)

Phase 3 Recruiting
158 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡